Angiodynamics Stock Price, News & Analysis

AngioDynamics (NASDAQ: ANGO) announced the enrollment of the first patient in the APEX-AV Study, evaluating the AlphaVac MMA F18⁸⁵ System for treating acute intermediate-risk pulmonary embolism (PE). Conducted at 20 U.S. hospital sites, the study aims to assess the device's efficacy and safety. Key endpoints include RV/LV ratio reduction and the rate of major adverse events within 48 hours. This trial, in partnership with The PERT Consortium and Viz.ai, aims to improve PE care using advanced AI recruitment strategies.

AngioDynamics, a medical technology company, reported net sales of $81.5 million for the first quarter of fiscal 2023, marking a 5.9% increase from the prior year. Med Tech sales rose by 29.6% to $22.8 million, driven by solid performances from the Auryon and thrombectomy platforms. However, Med Device sales declined by 1.1% to $58.7 million. The company experienced a gross margin decrease to 51.9% and reported a net loss of $13.0 million or $0.33 per share. Fiscal year 2023 guidance is reaffirmed, expecting net sales between $342 million and $348 million.

AngioDynamics, Inc. (NASDAQ: ANGO) will report its first quarter fiscal year 2023 financial results on October 6, 2022, before market open. Management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Investors can join the conference call by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international), using passcode 13732702. The call will be webcast on AngioDynamics' website, with a replay available shortly after the call.

AngioDynamics, Inc. (NASDAQ: ANGO) announced that Executive Vice President and CFO, Stephen Trowbridge, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast of the presentation on AngioDynamics' website, with a replay available afterward. The company focuses on innovative medical technologies aimed at restoring blood flow, enhancing cancer treatment options, and improving patient quality of life. More information is available at www.angiodynamics.com.

AngioDynamics, Inc. (NASDAQ: ANGO) reported its fourth quarter and fiscal year 2022 results, highlighting a 13.2% increase in net sales, totaling $87.0 million. However, gross margin decreased to 53.4%, down 170 basis points year-over-year. The company posted a GAAP loss per share of $0.16 for the quarter. For the full year, net sales reached $316.2 million, with a 8.7% increase over the previous year, but also a GAAP loss per share of $0.68. Looking ahead, AngioDynamics anticipates fiscal year 2023 net sales between $342 million and $348 million.

AngioDynamics, Inc. (NASDAQ: ANGO) will release its financial results for Q4 and fiscal year 2022 on July 12, 2022, before market open. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss the results. Investors can join via phone or through a webcast available on AngioDynamics' website. A recording of the call will be accessible from 11:00 a.m. ET on July 12 until 11:59 p.m. ET on July 19. The company focuses on innovative medical technologies aimed at improving vascular health and cancer treatment.

AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the UBS Global Healthcare Conference on May 23, 2022, at 4:15 p.m. ET. The presentation will focus on the company's innovations in medical technology aimed at restoring blood flow, enhancing cancer treatments, and improving patient quality of life. A live webcast will be available on the company’s website, with replay options following the event. AngioDynamics is recognized for addressing critical healthcare needs with its advanced technologies.

AngioDynamics, Inc. (NASDAQ: ANGO), a leader in medical technology, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the BofA Securities Healthcare Conference on May 10, 2022, at 10:00 a.m. PT (1:00 p.m. ET). The presentation can be viewed via live webcast on the company’s website and will be available for replay afterward. AngioDynamics specializes in restoring blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative healthcare solutions.

AngioDynamics reported a net sales increase of 3.9% to $74.0 million in Q3 fiscal 2022. Med Tech sales soared 28.6%, but Med Device saw a 2.8% decline. The gross margin decreased by 190 basis points to 52.2%. The company posted a GAAP loss per share of $0.13, though adjusted EPS rose to $0.03. Key FDA approvals were achieved for AlphaVac F18, and the company initiated the PRESERVE study. Despite challenges from COVID and inflation, AngioDynamics remains optimistic about long-term growth, projecting FY2022 net sales between $310 and $315 million.